- Yoh Dobashi, MDDepartment of Pathology, School of Medicine, International University of Health and WelfareInterests: Lung Cancer; Molecular Pathology; AKT; mTOR; microRNA; Gene Amplification
Dear Colleagues,
Lung cancer is still one of the most common malignancies world-wide and the leading cause of cancer death. Against the increasing incidence, screening by serum examination as well as diagnostic imaging gained subsequent higher detection rate in the early stage. Furthermore, as the therapeutic modality, recent progress of technique, machinery/tool and maneuverability in surgery greatly contributed to the improvement of treatment results. Finally, progress in precision medicine dealing with targeted agents have drastically changed the landscape of drug therapy, in particular, for adenocarcinoma. However, lung cancer is a sort of assembly by heterogeneous group, not only histologically, but also biologically, and thus, further clarification of the unknown patho-biological aspect of LC is inevitable. Based on this background, up-to-date notions for lung cancer is presented by experts in each field of lung cancer, i.e., pathologists, molecular biologists and surgeons.
Prof. Yoh Dobashi
Guest Editor
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
- Open Access ReviewMolecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?Hitomi Kawai, Ryouta Matsuoka, Takeshi Ito, Daisuke MatsubaraFront. Biosci. (Landmark Ed) 2022, 27(3), 108; https://doi.org/10.31083/j.fbl2703108(This article belongs to the Special Issue Lung cancer—recent advances in classification, diagnosis, basic research and therapy)279Downloads3Citations794Views
- Open Access Original ResearchDeveloping a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapyLiu Liu, Jingmian Zhang, Mark K. Ferguson, Daniel Appelbaum, ... Yonglin PuFront. Biosci. (Landmark Ed) 2022, 27(1), 16; https://doi.org/10.31083/j.fbl2701016(This article belongs to the Special Issue Lung cancer—recent advances in classification, diagnosis, basic research and therapy)51Downloads312Views
- Open Access ReviewCerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasisChi-Lu Chiang, Hsu-Ching Huang, Yung-Hung Luo, Chao-Hua ChiuFront. Biosci. (Landmark Ed) 2021, 26(12), 1679–1688; https://doi.org/10.52586/5060(This article belongs to the Special Issue Lung cancer—recent advances in classification, diagnosis, basic research and therapy)89Downloads3Citations287Views